Single-nuclei RNA sequencing characterizes cell types at the gene level. However, compared to single-cell approaches, many single-nuclei cDNAs are purely intronic, lack barcodes and hinder the study of isoforms. Here we present single-nuclei isoform RNA sequencing (SnISOr-Seq). Using microfluidics, PCR-based artifact removal, target enrichment and long-read sequencing, SnISOr-Seq increased barcoded, exon-spanning long reads 7.5-fold compared to naive long-read single-nuclei sequencing. We applied SnISOr-Seq to adult human frontal cortex and found that exons associated with autism exhibit coordinated and highly cell-type-specific inclusion. We found two distinct combination patterns: those distinguishing neural cell types, enriched in TSS-exon, exon-polyadenylation-site and non-adjacent exon pairs, and those with multiple configurations within one cell type, enriched in adjacent exon pairs. Finally, we observed that human-specific exons are almost as tightly coordinated as conserved exons, implying that coordination can be rapidly established during evolution. SnISOr-Seq enables cell-type-specific long-read isoform analysis in human brain and in any frozen or hard-to-dissociate sample.
and the influence of promoters on splicing are established\textsuperscript{24,25} for individual genes. Splicing can also influence TSS choice\textsuperscript{26}, and interactions between splicing and 3′-end cleavage have also been described\textsuperscript{27}. Likewise, the order of intron removal from the pre-mRNA has been tackled in yeast\textsuperscript{28}. However, how transcript element combinations specify cell types in the human brain remains unknown, limiting understanding of brain function. Similarly to the use of single alternative exons, the coordination status of transcript element combinations is an active area of research.

Fig. 1 | Overview of the SniSOr-Seq approach. a, Barcoded cDNA library of nuclei isolated from frozen human brain tissue. b, Three main types of molecules generated: spliced barcoded (known and novel isoforms), unspliced barcoded (exclusively intronic nucleotides) and incomplete cDNA without a cellular barcode. c, Linear/asymmetric PCR (‘LAP’) is used to selectively amplify barcoded cDNA. d, Probe-based exome capture (‘CAP’) step is applied to filter out purely intronic cDNA molecules. e, Molecules are sequenced on a long-read sequencer (PacBio and ONT).
elements observed in bulk can have origins from coordination in specific cell types or also from distinct isoforms in distinct cell types. We found that TSS–exon and exon–polyA site coordination follows a similar model to the coordination of distant alternative exons, whereas adjacent alternative exons follow a different model for cell type usage. Alternative splicing mis-regulation in disease is established{	extsuperscript{2,28,30}}, however, whether these exons are independently affected or hijacked in coordinated units is unknown. Using SnISOR-Seq's capacity for cell-type-specific long-read sequencing, we found that exons associated with distinct diseases exhibit distinct behavior in terms of (1) inclusion variability across cell types and (2) coordination. Despite common cortical roots, autism spectrum disorder (ASD)-associated exons show markedly different behavior than schizophrenia-associated and amyotrophic lateral sclerosis (ALS)-associated exons, with the caveat that distinct methods defined the exons associated to each disease.

**Results**

Removing single-cell artifacts and unspliced RNAs. We performed single-nuclei 3'-end sequencing of frontal cortex tissue from two healthy donors aged 68 and 61 years old from the Penn Brain Bank (hereinafter referred to as 'Cortex1' and 'Cortex2'; Methods). Employing standard protocols for single-cell analysis{	extsuperscript{31,32}}, we defined 12 clusters representing all major cortical cell types, including neurons, astrocytes, oligodendrocytes, microglia and vascular cells. Among neurons, we observed multiple inhibitory neurons, including SST{	extsuperscript{+}}, LAMPS{	extsuperscript{+}} and PVALB{	extsuperscript{+}} interneurons, and layer-specific excitatory neuron types: RORB{	extsuperscript{+}}, SEMA3E{	extsuperscript{+}} and LINCO0050{	extsuperscript{+}} (Fig. 2a and Supplementary Fig. 1a–r). We sequenced 8,376 unique molecular identifiers (UMIs) per cell of Cortex1, with excitatory neurons (subtype RORB and SEMA3E) showing the highest UMI counts per neuron and astrocytes and oligodendrocytes the lowest (Supplementary Fig. 2a). These UMI statistics were mirrored by similar gene-per-nucleus trends (Supplementary Fig. 2b). Both Cortex1 and Cortex2 showed high percentages of reads attributed to nuclei and low antisense mappings (Supplementary Fig. 2c). We then used 500 ng of full-length cDNA and performed linear/ asymmetric PCR and Agilent exome enrichments (LAP-CAP; Methods), followed by exponential/symmetric PCR. The resulting cDNAs were sequenced on eight (Cortex1) and seven (Cortex2) PacBio SMRT cells and three (Cortex1) and two (Cortex2) ONT PromethION flow cells. This yielded ~290×10{	extsuperscript{6}} long reads with average lengths of 0.9–1.2 kb across technologies and samples (Supplementary Table 1). As a negative control, we sequenced one SMRT cell per sample before LAP-CAP and one after LAP-CAP. We detected barcodes in long reads as recently published{	extsuperscript{12,33}}. The barcoded read fraction increased strongly from naive single-nuclei long-read sequencing to LAP-CAP (Fig. 2b). Likewise, on-target reads were markedly more frequent in LAP-CAP (Fig. 2b). We observed strong correlation in gene expression between Cortex1 and Cortex2 (r = 0.947; Fig. 2c), demonstrating SnISOR-Seq's replicability. When using all mapped reads (barcoded and unbarcoded), the correlation observed between Cortex1 before and after LAP-CAP was relatively strong (r = 0.881; Fig. 2d). However, SnISOR-Seq yielded a ~7.5-fold-higher fraction of 'usable' reads (that is, reads that were mapped, barcoded and on-target) compared to naive long-read single-nuclei sequencing (30.6% versus 4.06%; Fig. 2b).

We found that, despite being deployed in a considerably more complex environment (frozen tissue, nuclei and large postmortem intervals), SnISOR-Seq was almost on par with ScISOR-Seq in fresh cells for transcript coverage bias, read length and exon count. Read length differences accounted for much, but not all, of the observed coverage differences between short and long reads (Methods and Supplementary Fig. 3a–c). We consider a read 5’ and/or 3’ complete if the start and/or end overlap a 50-bp window of published Cap Analysis of Gene Expression (CAGE) and polyA peaks, respectively (Supplementary Fig. 3d and Methods). We found that SnISOR-Seq provides fewer complete molecules, probably due to intron retention and the fragmented nature of nuclear RNA from postmortem tissue. Especially on the 3’ end, large introns are detrimental to producing full-length molecules (Supplementary Fig. 3e,f). Consequently, SnISOR-Seq covers ~57.1% of the expected exons per transcript in each read, whereas ScISOR-Seq yields close to all expected exons (Methods and Supplementary Fig. 3g,h). Subsampling simulations showed that genes and pairs of isoform features all approached saturation at full sequencing depth (Supplementary Fig. 3i). Similarly to recent bulk PacBio RNA sequencing of human cortex{	extsuperscript{34}}, detected genes plateaued at ~12,000. For initiating reverse transcription, simulations suggest that poly(dT) priming captures entire polyadenylated molecules. However, RNA fragments lacking a polyA tail might be missed by poly(dT) primers, whereas some of their sequence might be captured by random hexamers (Methods and Supplementary Fig. 4a). At a sequencing depth of ~1.1 million long reads, LAP-CAP sample had one UMI per 1.06 barcoded reads compared to one UMI per 1.001 for the pre-LAP-CAP sample (Supplementary Fig. 4b). However, for 20×10{	extsuperscript{6}} long reads, the LAP-CAP sample yielded one UMI per 1.46 reads (Supplementary Fig. 4c,d). SnISOR-Seq in human nuclei even outperformed ScISOR-Seq in fresh mouse samples in usable reads, and both methods were on par for exons per spliced read (Supplementary Fig. 4e,f).

Lastly, SnISOR-Seq was clearly advantageous in recovering fully spliced reads as compared to unspliced and partially spliced reads (Supplementary Fig. 4g,h), although only 41% of 5’ read ends and 52% of 3’ read ends corresponded to CAGE and polyA peaks, respectively (Supplementary Fig. 3e,f).

The ONT datasets had 515 and 384 median reads per nucleus for Cortex1 and Cortex2, respectively (Supplementary Fig. 5a,b). The four major cell types (astrocytes, oligodendrocytes, excitatory neurons and inhibitory neurons) represented 77.9% (Cortex1) and 82.6% (Cortex2) of nuclei (Supplementary Fig. 5c,d), and excitatory neurons consistently had the most reads, UMIs and genes per nucleus (Supplementary Fig. 5e–j). Of note, excitatory neurons had higher counts in Cortex2, mostly at the expense of oligodendrocytes and astrocytes (Supplementary Fig. 5). The ONT LAP-CAP data were sequenced to greater depth than the PacBio libraries. However, both datasets highly correlated for reads per gene and identified splice sites and exon inclusion levels (Supplementary Fig. 6a–d).

Single-exon patterns reveal variable inclusion across cell types, including for ASD-associated exons. Despite their short length, microexons (here defined as ≤27 nucleotides (nt)) are conserved, highly included in neurons and harbor biological functions{	extsuperscript{35}}. Using alternative exons (Methods) whose genes are expressed in the four major cell types, we calculated their ψ (percent spliced-in) values and considered the maximal ΔΨ (Methods) between these cell types for Cortex1 (Fig. 3a). Building on previous observations{	extsuperscript{35–37}}, the most variable exons were enriched in microexons (<27 nt). However, highly variable exons with high ψ in neuronal or non-neuronal cell types were also enriched for exons ≤54 nt—that is, twice the maximal length for microexons and, albeit less pronounced, for ≤75 nt (Fig. 3b). Thus, cell-type-specific exon inclusion separates shorter exons from longer ones although far beyond the strict microexon definition. Cell-type-specific inclusion of disease-associated exons can pinpoint disease-implicated cell types. We, therefore, investigated published exons associated with schizophrenia{	extsuperscript{38}}, ASD{	extsuperscript{35,39,40}} and ALS{	extsuperscript{41}} for inclusion variability across cell types. Separating our 5,855 alternative exons into schizophrenia-associated and non-schizophrenia-associated exons, we found no significance (two-sided Wilcoxon rank-sum test, P = 0.13) and only a 1.2-fold ratio between the two medians. Likewise, considering ALS, we found a fold change of ratio close to 1, albeit with a significant P value in one replicate. Thus, the schizophrenia-associated...
exons used here behave largely like random alternative exons in terms of cell-type-specific inclusion. ASD-associated exons, however, behaved differently. ASD-associated exons were considerably more variable across cell types (two-sided Wilcoxon rank-sum test, \( P < 2.22 \times 10^{-16} \)), with a 2.2-fold-higher median than non-ASD-associated alternative exons. The genes from which these disease-associated exons are derived were largely distinct for each disease considered and had no significant gene expression variability between the cell types (Supplementary Fig. 7a,b). Additionally, to control for previous observations regarding microexons in ASD, we excluded microexons from our comparative analysis, and the observation remained true (Fig. 3c). We found four novel exon subsets: high variability and high inclusion (\( n = 6 \), top right); high variability but low inclusion (\( n = 20 \), top left); high inclusion but low variability (\( n = 30 \), bottom right); and low inclusion and low variability (\( n = 206 \), bottom left). Although all novel exons could be impactful, and the 0.5 cutoff is arbitrary, the first three categories suggest very high importance in at least one cell type (Fig. 3e). The above observations were broadly replicable in Cortex2 (Supplementary Fig. 7d–g). CADM1 illustrates multiple highly cell-type-specific alternative exons in one gene (Fig. 3f). Three alternative exons are included more in astrocytes, oligodendrocyte precursor cells (OPCs) and oligodendrocytes than in both neuron types. Two alternative exons (Alt. exon 2 and Alt. exon 3; Fig. 3f) are very highly included in astrocytes. The inclusion in glia and ASD association of Alt. exon 3 motivates the exploration of its possible glial mis-regulation in ASD. In the event that new disease-associated exons are published, these can be explored on our interactive web portal (https://isoformatlas.com/).

**Combinations of transcript elements show distinct pairing rules.** We and others have investigated patterns of exon combinations; however, the frequency of different combination patterns remains unclear. Two exons may be paired non-randomly (that is, treatment-specific) with each other, they may be paired randomly, or they may be mutually exclusive, pairing with another exon. To address this question, we analyzed the pairing of all exons in each sample. We identified four categories of pairing patterns: high variability and high inclusion, low variability and high inclusion, high variability and low inclusion, and low variability and low inclusion. The percentage of exons in each category is shown in Supplementary Fig. 7c. The results suggest that exons are paired randomly, suggesting that the pairing of exons is not treatment-specific.
**Fig. 3 | Alternative usage of single exons.**

**a.** Schematic illustrating percent spliced-in (Ψ) calculation for an alternative exon (green). The exon shows different levels of inclusion across three cell types, with variability defined as maxΨ − minΨ. **b.** Density plot of the exon variability across the four major cell types and exon length on the x axis. Colors indicate the discrete categories of variability. **c.** Box plots of the exon variability for alternative disease-associated exons (red) compared to alternative exons with no known association with that disease (green). P values obtained from a two-sided Wilcoxon rank-sum test. Investigated diseases are represented on the x axis (n = 46; 1,580; 69; 1,557; 227; and 1,399 exons). **d.** Heat map of the exon inclusion level for ASD-associated exons where each row is an exon and each column is a cell type. Annotation of exon classification as a microexon (≤27 bp; green) and other exons (>27 bp; pink) on the left. Color scale of the heat map indicates Ψ value. **e.** Scatter plot of the Ψ of pseudo-bulk (that is, across all nuclei) on the x axis and exon variability across cell types on the y axis. Points indicate novel exons that had ≥10 reads in ≥2 cell types. Regression curve with 95% confidence interval obtained using the loess fit. Boundaries of low and high variability and inclusion defined at 0.5 on both axes. **f.** Full-length transcript expression by cell type for the CADM1 gene. Each horizontal line indicates one transcript, colored by cell type; clustered blocks denote exons. Black denotes annotated GENCODE transcripts. Purple boxes highlight three alternative exons: AE1–AE3. For box plots: center line, median; box limits, upper and lower quartiles; and whiskers, 1.5× interquartile range.
in a coordinated fashion) or randomly. The former can represent a tendency for mutual association or exclusion (Fig. 4a). When two exons within a transcript are coordinated (mutually associated/exclusive) in pseudo-bulk, we investigate if this is also true in ≥1 cell type (Supplementary Fig. 8a,b). Our testing strategy is similar to previous approaches and performs similarly to previous approaches and performs similarly (Supplementary Fig. 8c). For our analysis of exon coordination, we first considered alternative exon pairs. After false discovery rate (FDR) calculation, only one exon pair per gene was retained to avoid patterns representing few genes with many exon pairs (Methods). Among neighboring exon pairs, 71.4% of tested pairs, each represented by a 2×2 table, showed a significant association at FDR=0.05 and log-odds ratio ≥ 1. By definition, this fraction decreases for higher log-odds ratios. However, even for a log-odds ratio ≥ 7, that is, a 128-fold enrichment of two of the exon combinations over the other two, ≥50% of exon pairs showed non-random pairing (Fig. 4b). For distant alternative exon pairs—that is, those with intervening exons, which we investigated previously—that fraction was substantially lower (Fig. 4c). An example of neighboring coordinated exons is the WDR49 gene. Two neighboring coding exons are positively and perfectly coordinated—that is, all molecules include either both exons or none, whereas molecules with only one exon are not observed. In this case, coordination of both exons originates from an individual cell type, namely astrocytes (Fig. 4d). Adjacent coordinated alternative exons showed stronger coordination than distant coordinated exon pairs (Fig. 4e). Furthermore, distant exon pairs frequently show mutual exclusion coordination—which is a negative log-odds ratio, whereas this is considerably less likely for adjacent exon pairs (Fig. 4f), which dominate our dataset. Compared to non-coordinated exon pairs, coordinated exon pairs were separated by smaller introns and had weaker acceptor sequence similarity between these exon pairs. Given their tight coordination, we hypothesized that coordinated adjacent exon pairs are included/skipped in ≥1 cell type than adjacent alternative exons (Fig. 4i). This finding was replicated in each cell type separately, although non-overlapping 95% confidence intervals were observed only in excitatory neurons, inhibitory neurons and oligodendrocytes (Fig. 4d).

In addition to, and partially based on, our previous observation of ASD-associated exons being more variably spliced than others, we also found that pairs of ASD-related exons are highly coordinated. Indeed, ASD-associated exons are part of a distant coordinated exon pair more frequently than exons not associated with ASD (two-sided Fisher’s exact test, P=1.82×10−6; Fig. 5c and Supplementary Fig. 10c). An example of distant coordinated ASD-associated exons with a strong cell-type-specific component is the PTK2 gene, which encodes for FAK and influences axonal growth regulation and neuronal cell migration. Two alternative microexons of 18 bp and 21 bp are highly included in excitatory and inhibitory neurons (co-inclusion score = 0.8 and 0.7; Methods) but are almost completely skipped in glial types (co-inclusion score = 0.02 and 0, respectively, for astrocytes, oligodendrocytes and OPCs). We validated this highly cell-type-specific inclusion of these two exons using qRT–PCR (Methods and Supplementary Fig. 10d,e). Additionally, six of ten tryptic peptides obtained from ASD-associated exons that were detectable in mouse cell-type-specific proteome data showed the same cell-type-specific tendencies as the human exons (Methods and Supplementary Fig. 10f). This further motivates single-cell long-read investigations of ASD.

Coordination of exon pairs observed in bulk mostly stems from coordination in specific cell types. We then examined whether the coordination patterns at pseudo-bulk level were detected in at least one high-level cell type or whether they represent a heterogeneous mixture of homogeneous cell-type-specific patterns. Here, we considered excitatory neurons, inhibitory neurons, astrocytes, oligodendrocytes and OPCs as high-level cell types. Among the mostly adjacent coordinated pseudo-bulk exon pairs testable in ≥1 cell type, 89% were significantly coordinated in ≥1 cell type, meaning that the same patterns of coordination were observed in one or more cell types. More precisely, 41.7% were coordinated in one cell type, 21.3% in two cell types and 24% in three, four or five cell types (Fig. 5a). These observations were broadly conserved in Cortex2 (Supplementary Fig. 10a). In all five cell types investigated, ≥50% of testable (mostly adjacent) exon pairs showed significant coordination, but percentages varied among cell types. Indeed, for astrocytes, only 54.08% showed coordination, whereas, for oligodendrocytes and OPCs, 67.14% and 72.72% showed coordination, respectively (Fig. 5b and Supplementary Fig. 10b). Two distinct models can explain why an exon pair that is testable in pseudo-bulk is not testable in a cell type. First, read counts in a cell type, which are, by definition, lower than or equal to those in the pseudo-bulk, might simply be too low to allow for χ² testing—a model purely technical in nature. Second, one or both of the exons might become constitutively included or skipped in the cell type (Methods and Supplementary Fig. 8b); this implies that the χ² criterion for testability is violated—a model biological in nature. Distant alternative exon pairs are ~2-fold more likely to have ≥1 exon constitutively included/skipped in ≥1 cell type than adjacent alternative exons (Fig. 5c). This finding was replicated in each cell type separately, although non-overlapping 95% confidence intervals were observed only in excitatory neurons, inhibitory neurons and oligodendrocytes (Fig. 5d).
All significant cell-type-specific exon coordination values pointed in the same direction as in the pseudo-bulk. That is, coordination values for adjacent exon pairs observed in bulk reflect coordination in ≥ 1 cell type. Neurons and astrocytes clearly recapitulated more coordination events from the pseudo-bulk than oligodendrocytes and OPCs, likely owing to their higher nuclei numbers (Fig. 5g). Additionally, because of the strong tendency for mutual inclusion for adjacent exons, most molecules represent the mutually associated exons. In Cortex2, excitatory neurons dominated the genes that were significantly coordinated in bulk due to high excitatory neuron number in Cortex2 (Supplementary Fig. 10g).

Consistent with our pseudo-bulk observations, we found no significant association between exon conservation and coordination at cell type level (excitatory neurons as a representative cell type; Fig. 5h). In contrast to this observation, conservation was significantly associated with the inclusion of both alternative exons, an observation replicable in Cortex2 (Fig. 5i and Supplementary Fig. 10h,i).

TSS–exon and exon–polyA site coordination often stems from constitutive use of variable sites in distinct cell types. When tracing coordinated exon–TSS events into five major cell types, we observed considerably different behavior than that of adjacent exon
Fig. 5 | Exon coordination patterns are observable across multiple cell types. a. Pie chart of number of cell types where an exon pair is significant given significance in pseudo-bulk. b. Bar plot of percentage of tested exon pairs (one per gene) that were significantly coordinated. Cell type on the x axis (n = 98, 121, 101, 70 and 33). c. Bar plots of percentage of genes that are not testable in any cell type because at least one exon became constitutive. x axis values indicate adjacent (n = 114) or distant (n = 23). d. Bar plots of percentage of genes that are not testable in specific cell types because at least one exon became constitutive, colored by adjacent (n = 31, 31, 26, 22) or distant (n = 15, 15, 15, 15 and 14) exon pairs. e. Bar plot showing percent of distant coordinated exon pairs split by ASD association (n = 67 and 241). P value obtained from two-sided Fisher’s exact test. b–e. Error bars indicate s.e. of the point estimate. f. Distantly coordinated exons for the PTK2 gene. Each horizontal line indicates one transcript, colored by cell type; clustered blocks indicate exons. Gray denotes annotated GENCODE transcripts. Blue boxes highlight coordinated exons, labeled Alt. exon 1 and Alt. exon 2. Control exon for qRT–PCR highlighted in blue. g. Heat map showing exon pairs that were testable in at least one cell type (n = 127). Exon pairs colored by significant coordination in same (pink) or opposite (blue) direction as pseudo-bulk, not significant (white), not testable in a particular cell type because of low counts (gray) or exons becoming constitutive (teal). h. Box plots of the log-odds ratio of excitatory neuron reads for tested exon pairs versus the minimum PhastCons score being <0.5 (n = 26) or >0.5 (n = 93). i. Box plots of the ratio of double inclusion of an exon pair to coordination (for excitatory neurons). x axis as same as in h. For box plots: center line, median; box limits, upper and lower quartiles; and whiskers, 1.5 interquartile range. P values (h, i) calculated using the two-sided Wilcoxon rank-sum test. Significance: *P < 0.05; **P < 0.005; ***P < 0.001; NS, not significant. Astro, astrocyte; EN, excitatory neuron; IN, inhibitory neuron; Oligo, oligodendrocyte.

Discussion

Elucidating combination patterns of transcript elements—TSSs, exons and polyA sites—is necessary for a comprehensive understanding of biology, because these patterns define full-length isoforms carrying protein-coding information. To identify affected cell-type-specific splicing patterns in disease, it is paramount to
first understand the combinations in healthy tissue, particularly of disease-associated exons. Moreover, brain region and cell-type-specific isoform expression might be critical to understanding the clinical relevance of deleterious variants of uncertain importance observed in patient genomes. To investigate these questions, we developed SnISOr-Seq (Fig. 1), an approach applicable to...
any single-nuclei RNA sequencing library. Although single-nuclei RNA sequencing is employed for many tissues, it is especially relevant for frozen samples, for which whole-cell isolation is difficult, a prominent example being the human brain.

SnISOr-Seq reveals single and combinatorial usage patterns of transcript elements. Consistent with previous reports, we found that microexons (that is, exons ≤27bp) show more variable inclusion across cell types than longer exons. However, exons considerably longer than 27bp (up to ~75bp depending on variability cutoff) also show high variability. ASD-associated exons, even when excluding microexons, show higher inclusion variability across the four major cell types than random alternative exons. In contrast, the trend for schizophrenia-associated or ALS-associated exons is substantially weaker or non-existent. In other words, although a fraction of ASD-associated exons exhibit similar inclusion in the four major cell types, a greater proportion show cell type specificity than for other diseases. The contrast between ASD and ALS/schizophrenia has the caveat that experiments to define disease-associated exons differ. However, should new exon–disease associations be identified, such exons can be queried against our data on our online interface (https://isofomatlas.com/). ASD-associated exons can have high glial, neuronal or uniform inclusion. The presence of both cell-type-biased and unbiased patterns implies that these exons are not well investigated by fluorescence-activated cell sorting (FACS) a single cell type. Single-cell investigations of exon pairing might be even more relevant for schizophrenia-associated and ALS-associated exons, which are no more variably included across cell types than background exons. These observations raise the fundamental question of whether, in disease, the inclusion of these disease-associated exons are altered in all cell types equally or whether their Ψ values change in particular cell types. Ample research has investigated exon pairs, TSS–exon pairs and exon–polyA site pairs. However, until now, a comparative analysis of these had been lacking in human brain. We found that adjacent exon pairs are combined more often and less randomly than distant pairs. In fact, most genes tested showed coordination of ≥1 adjacent exon pair. The gene fraction with coordinated exons could increase even further with deeper sequencing. Moreover, adjacent coordinated alternative exons are almost always mutually inclusive, whereas distant alternative exons exhibit more mutual exclusivity. TSS–exon pairing and exon–polyA site pairing show similar coordination to distant alternative exons but significantly less than adjacent exon pairs.

Considering cell-type-specific RNA expression, we found that three types of coordination, namely TSS–exon, exon–polyA site and distant exon–exon coordination, follow the same rule: these types of coordination are often observed at the pseudo-bulk level but are rarely traced into distinct human brain cell types. Often, they arise by one combination being expressed in one cell type and a different combination occurring in another. Thus, these types of coordination most often reflect the diversity of isoform expression distinguishing cell types (Extended Data Fig. 1a–c). Adjacent alternative exons, however, usually follow another pattern: whenever read counts suffice to trace coordination into specific cell types, we usually find one cell type, and often multiple cell types, in which this coordination occurs (Extended Data Fig. 1d).

Thus, when mutual association versus exclusivity and cell type specificity of coordination are considered, TSS–exon, polyA–site exon and distant exon pairs follow one model, whereas adjacent exon pairs follow a markedly different one. ASD-associated exons in distant exon pairs are more likely to be cell type specific and coordinated than non-ASD exons. Thus, splicing investigations of the brain in general and a deeper understanding of the role of these exons in neurological disease can benefit from further investigations enabled by SnISOr-Seq. The technologies developed here will also facilitate cross-species comparisons of cell-type-specific splicing.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41587-022-01231-3.

Received: 29 June 2021; Accepted: 20 January 2022; Published online: 7 March 2022

References
1. Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202–1214 (2015).
2. Klein, A. M. et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187–1201 (2015).
3. Zeisel, A. et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138–1142 (2015).
4. Sharon, D., Tilgner, H., Grubert, F. & Snyder, M. A single-molecule long-read survey of the human transcriptome. Nat. Biotechnol. 31, 1099–1104 (2013).
5. Au, K. F. et al. Characterization of the human ESC transcriptome by hybrid sequencing. Proc. Natl. Acad. Sci. USA 110, E4821–E4830 (2013).
6. Koren, S. et al. Hybrid error correction and de novo assembly of single-molecule sequencing reads. Nat. Biotechnol. 30, 693–700 (2012).
7. Tilgner, H. et al. Comprehensive transcriptome analysis using synthetic long-read sequencing reveals molecular co-association of distant splicing events. Nat. Biotechnol. 33, 736–742 (2015).
8. Okonkomopoulos, S., Wang, Y. C., Djambazian, H., Badescu, D. & Ragooussis, J. Benchmarking of the Oxford Nanopore MinION sequencing for quantitative and qualitative assessment of cDNA populations. Sci. Rep. 6, 31602 (2016).
9. Karlsson, K. & Linnarsson, S. Single-cell mRNA isoform diversity in the mouse brain. BMC Genomics 18, 126 (2017).
10. Volden, R. et al. Improving nanopore read accuracy with the R2C2 method enables the sequencing of highly multiplexed full-length single-cell cDNA. Proc. Natl. Acad. Sci. USA 115, 9726–9731 (2018).
11. Singh, M. et al. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nat. Commun. 10, 3120 (2019).
12. Gupta, I. et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. Nat. Biotechnol. 36, 1197–1202 (2018).
13. Hodge, R. D. et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61–68 (2019).
14. Krishnaswami, S. R. et al. Using single nuclei for RNA-seq to capture the transcriptome of postmortem neurons. Nat. Protoc. 11, 499–524 (2016).
15. Lake, B. B. et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586–1590 (2016).
16. Bergen, V., Lange, M., Peidli, S., Wolf, E. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408–1414 (2020).
17. La Manno, G. et al. RNA velocity of single cells. Nature 560, 494–498 (2018).
18. Lange, M. et al. CellRank for directed single-cell state mapping. Nat. Methods https://doi.org/10.1038/s41592-021-01346-6 (2022).
19. Eid, J. et al. Real-time DNA sequencing from single polymerase molecules. Science 323, 133–138 (2009).
20. Tilgner, H. et al. Microfluidic isoform sequencing shows widespread splicing coordination in the human transcriptome. Genome Res. 28, 231–242 (2018).
21. Anvar, S. Y. et al. Full-length mRNA sequencing uncovers a widespread coupling between transcription initiation and mRNA processing. Genome Biol. 19, 46 (2018).
22. Schreiner, D. et al. Targeted combinatorial alternative splicing generates brain region-specific repertoires of neurexins. Neuron 84, 386–394 (2018).
23. Treutlein, B., Gokce, O., Quake, S. R. & Sudhof, T. C. Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc. Natl. Acad. Sci. USA 111, E1291–E1299 (2014).
24. Fededa, J. P. et al. A polar mechanism coordinates different regions of alternative splicing within a single gene. Mol. Cell 19, 393–404 (2005).
25. Cramer, P., Pese, C. G., Baralle, F. E. & Kornblith, A. R. Functional association between promoter structure and transcript alternative splicing. Proc. Natl. Acad. Sci. USA 94, 11456–11460 (1997).
26. Fiszbein, A., Krick, K. S., Begg, B. E. & Burge, C. B. Exon-mediated activation of transcription starts. Cell 179, 1551–1565 (2019).
27. Reiner, K. A., Mimoso, C. A., Adelman, K. & Neugebauer, K. M. Co-transcriptional splicing regulates 3’ end cleavage during mammalian erythropoiesis. Mol. Cell 81, 998–1012 (2021).
28. Herzl, L., Straube, K. & Neugebauer, K. M. Long-read sequencing of nascent RNA reveals coupling among RNA processing events. *Genome Res.* **28**, 1008–1019 (2018).

29. Parras, A. et al. Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing. *Nature* **560**, 441–446 (2018).

30. Zhang, Y. et al. Regional variation of splicing QTLs in human brain. *Am. J. Hum. Genet.* **107**, 196–210 (2020).

31. Stuart, T. et al. Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902 (2019).

32. Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049 (2017).

33. Joglekar, A. et al. A spatially resolved brain region- and cell type-specific isoform atlas of the postnatal mouse brain. *Nat. Commun.* **12**, 463 (2021).

34. Leung, S. K. et al. Full-length transcript sequencing of human and mouse cerebral cortex identifies widespread isoform diversity and alternative splicing. *Cell Rep.* **37**, 110022 (2021).

35. Irimia, M. et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. *Cell* **159**, 1511–1523 (2014).

36. Li, Y. I., Sanchez-Pulido, L., Haerty, W. & Ponting, C. P. RRFOX and PTBP1 proteins regulate the alternative splicing of micro-exons in human brain transcripts. *Genome Res.* **25**, 1–13 (2015).

37. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).

38. Takata, A., Matsumoto, N. & Kato, T. Genome-wide identification of splicing QTLs in the human brain and their enrichment among schizophrenia-associated loci. *Nat. Commun.* **8**, 14519 (2017).

39. Parikshak, N. N. et al. Genome-wide changes in IncRNA, splicing, and regional gene expression patterns in autism. *Nature* **540**, 423–427 (2016).

40. Gonatopoulos-Pournatzis, T. & Blencowe, B. J. Microexons: at the nexus of nervous system development, behaviour and autism spectrum disorder. *Curr. Opin. Genet. Dev.* **65**, 22–33 (2020).

41. Wang, Q., Conlon, E. G., Manley, J. L. & Rio, D. C. Widespread intron retention impairs protein homeostasis in C9orf72 ALS brains. *Genome Res.* **30**, 1705–1713 (2020).

42. Uszczynska-Ratajczak, B., Lagarde, J., Frankish, A., Guigó, R. & Johnson, R. Towards a complete map of the human long non-coding RNA transcriptome. *Nat. Rev. Genet.* **19**, 535–548 (2018).

43. Zhu, C. et al. Single-molecule, full-length transcript isoform sequencing reveals disease-associated RNA isoforms in cardiomyocytes. *Nat. Commun.* **12**, 4203 (2021).

44. Parra, G., Blanco, E. & Guigó, R. GeneID in *Drosophila*. *Genome Res.* **10**, 511–515 (2000).

45. Ye, T. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J. Comput. Biol.* **11**, 377–394 (2004).

46. Abascal, F. et al. Alternatively spliced homologous exons have ancient origins and are highly expressed at the protein level. *PLoS Comput. Biol.* **11**, e1004325 (2015).

47. Siepel, A. et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. *Genome Res.* **15**, 1034–1050 (2005).

48. Liu, G. et al. Netrin requires focal adhesion kinase and Src family kinases for axon outgrowth and attraction. *Nat. Neurosci.* **7**, 1222–1232 (2004).

49. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372 (2008).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2022
Pre-frontal cortex samples for Illumina sequencing of bulk nuclei. Pre-frontal cortex (PFC) samples from two patients with Alzheimer’s disease used for Illumina sequencing were obtained from the Human Brain Tissue Bank (HBTB; Semmelweis University), which is a member of the BrainNet Europe II. HBTB’s activity is authorized by the Committee of Science and Research Ethics of the Ministry of Health Hungary (ETT TUEKB: 189/KO/62.6008/2002/ETT) and the Semmelweis University Regional Committee of Science and Research Ethics (32/1992/TUKEB), including human brain tissue sample removal, collecting and storing and applying for research. Human brain microdissection procedures were approved by the Regional and Institutional Committee of Science and Research Ethics of Scientific Council of Health (ethical license: 34/2002/TUKEB-11716/2013/EHR) and the Code of Ethics of the World Medical Association (Declaration of Helsinki). Genetic testing and international transportation samples were authorized by the Semmelweis University Regional Committee of Science and Research Ethics (34/2002/TUKEB). The postmortem interval was 6.5 h for PFC_S1 (age 93, female) and 5 h for PFC_S2 (age 81, male). In both cases, the tissue samples were micro-dissected from the dorsolateral PFC (middle frontal gyrus, Brodmann area 9). The micropunch procedure consisted of slicing the PFC into serial coronal sections, micropunching from both the surface and the deep (wall of the superior frontal sulcus) parts of the gyrus and collecting tissue pellets. Until processing, the brains were frozen and kept at −80°C.

Fetal human samples for qRT-PCR validation. Neurons (Thy1+ cells) and astrocytes (HepaCAM+ cells) were isolated from fetal human brain tissue (n = 3, gestational weeks 19–20) using the immunopanning method. The fetal human brain tissue samples were obtained with informed consent under a Stanford University institutional review board-approved protocol.

Single-nuclei isolation and 10x Genomics 3′ library construction. Single-nuclei sample was isolated from fresh-frozen human brain samples with modifications from a previous protocol.[12,13] Next, ~30 ng of frozen tissue per sample was dissected in a sterile dish on dry ice and transferred to a 2-ml glass tube containing 1.5 ml of nuclei lysis buffer (MilliporeSigma, L9826) on ice. Tissue was completely mixed and homogenized to nuclei sample by suspension grinding with Dounce homogenizers (Sigma, D9839–1SET) with 20 strokes with pestle A and 18 strokes with pestle B. The nuclei suspension was filtered through a 35-µm-diameter filter and followed by centrifuging for 5 min at 600 g and 4°C. The nuclei pellet was collected and washed with cold wash buffer 1 (WB1) which contains the following reagents: 1× PBS (Corning, 46-013-CM), 20 mM DTT (Thermo Fisher Scientific, P2325), 1% BSA (NEB, B900008) and 0.2 µl/ml of RNase inhibitor (Ambion, AM2682) for three times. After removing the supernatant from the last wash, nuclei were resuspended in 1 ml of 0.5 µg/ml of DAPI (Sigma, D9542) containing wash buffer to stain for 15 min. The nuclei suspension was prepared for sorting by filtering cell aggregates and particles out with a diameter of 35 µm. Nuclei were sorted to remove cell debris and fractured nuclei using the Sony MA900 sorter with Flowio version 10 software (Supplementary Fig. 12a–c). These were collected by centrifuging for 5 min at 600 g and 4°C and then resuspended in wash buffer to reach a final concentration of 1 × 105 nuclei per milliliter after counting in trypan blue (Thermo Fisher Scientific, T10282) using a Countess II cell counter (Thermo Fisher Scientific, A27977).

10x Genomics 3′ library construction was performed by following the manufacturer’s instructions with single-nucleus suspension obtained from the last step. 10x Genomics 3′ libraries of Cortex1 and Cortex2 were loaded on an Illumina NovaSeq 6000 with PE 2 × 100 paired-end reads by using the following read length: 24 cycles Read1, eight cycles i7 index and 96 cycles Read2.

Linear/asymmetric PCR steps to remove non-barcoded cDNA. The first round PCR protocol (95°C for 3 min, 12 cycles of 98°C for 20 s, 64°C for 30 s and 72°C for 60 s) was performed by applying 12 cycles of linear/asymmetric amplification to preferentially amplify one strand of the cDNA template (30 ng of cDNA generated by using 10X Genomics Chromium Single Cell 3′ Gem kit) with primer ‘Partial Read1’ and then the product was purified with 0.8x SPRIselect beads (Beckman Coulter, B23318) and washed twice with 80% ethanol. The second round PCR is performed by applying four cycles of exponential amplification under the same condition with forward primer ‘Partial Read1’ and reverse primer ‘Partial TSO’ and then the product was purified with 0.8x SPRIselect beads (Beckman Coulter, B23318) and washed twice with 80% ethanol and eluted in 30 µl of buffer EB (Qiagen, 19086). Sequences of primers: Partial Read1 (5′-CTACAGAGCCTCTTCGGCTAGTCT-3′) and Partial TSO (5′-AAGCAGTGTTACAAACGGAGTACAT-3′). KAPA HiFi HotStar PCR Ready Mix (2x) (Roche, KK2601) was used as polymerase for all the PCR amplification steps in this paper, except for the 10x Genomics 3′ library construction part.

Exome capture to enrich for spliced cDNA. Exome enrichment was applied to the cDNA purified from the previous step by using probe kit SELLXT Human All exon V8 (Agilent, 5191-8679) and the reagent kit SureSelectXT HSQ (Agilent, G9611A), according to the manufacturer’s manual. First, the block oligo mix was made by mixing an equal amount (1 µl of each per reaction) of primers Partial Read1 (5′-CTACAGAGCCTCTTCGGCTAGTCT-3′) and Partial TSO (5′-AAGCAGTGTTACAAACGGAGTACAT-3′) with the concentration of 200 ng µl−1 (IDT), resulting in 100 ng µl−1. Next, 5 µl of 100 ng µl−1 cDNA diluted from the previous step was combined with 2 µl of block mix and 2 µl of nucleic free water (NEB, AM9937), and then the cDNA block oligo mix was incubated on a thermocycler under the following conditions to allow blocking to bind to the 5′ end and the 3′ end of the cDNA molecule: 95°C for 5 min, 65°C for 5 min and 65°C on hold. For the next step, the hybridization mix was prepared by combining 20 µl of SureSelect Hyb1, 0.8 µl of SureSelect Hyb2, 8.0 µl of SureSelect Hyb3 and 10.4 µl of SureSelect Hyb4 and kept at room temperature. Once the reaction reached to 65°C on hold, 5 µl of probe, 1.5 µl of nucleic-free water, 0.5 µl of 1.4 diluted RNase Block and 13 µl of the hybridization mix were added to the cDNA block oligo mix and incubated for 24 h at 65°C. When the incubation reached the end, the hybridization reaction was transferred to room temperature. Simultaneously, an aliquot of 75 µl of M-270 Streptavidin Dynabeads (Thermo Fisher Scientific, 65305) were prepared by washing three times and resuspended with 200 µl of binding buffer. Next, the hybridization reaction was mixed with all the M-270 Dynabeads and placed on a Hula mixer for 30 min at room temperature. During the incubation, 600 µl of wash buffer 2 (WB2) was transferred to three wells of a 0.2-ml PCR tube and incubated in a thermocycler on hold at 65°C. After the 30-min incubation, the buffer was replaced with 200 µl of wash buffer 1 (WB1). Then, the tube containing the hybridization product bound to M-270 Dynabeads was put back into the Hula mixer for another 15-min incubation with low speed. Next, the WB1 was replaced with WB2, and the tube was transferred to the thermocycler for the next round of incubation. Overall, the hybridization product bound to M-270 Dynabeads was incubated in WB2 for 30 min at 65°C, and the buffer was replaced with fresh pre-heated WB2 every 10 min. When the incubation was over, WB2 was removed, and the beads were resuspended in 18 µl of nucleic-free water and stored at 4°C. Next, the spliced cDNA, which bound with the M-270 Dynabeads, was amplified with primers Partial Read1 and Partial TSO by using the following PCR protocol: 95°C for 3 min, 12 cycles of 98°C for 20 s, 64°C for 60 s and 72°C for 3 min. The amplified spliced cDNA was isolated from M-270 beads as supernatant and followed by a purification with 0.6x SPRIselect beads.

Library preparation for PacBio. HiFi SMRTbell libraries of Cortex1 and Cortex2 were constructed according to the manufacturer’s manual by using SMRTbell Express Template Prep Kit 2.0 (PacBio, 100-938-900). For both samples, ~500 ng of cDNA was isolated by performing LAP-CAP from the PFC cortex (PFC) samples from two patients with Alzheimer’s disease used for Illumina sequencing. The ONT library was loaded onto a PromethION sequencer by using PromethION Flow Cell (ONT, FLO-PRO0002) and sequenced for 72h.

Library preparation for ONT. For both samples, ~75 fmol cDNA was processed through high LCP-LAP CAP underwent the Ligation Sequencing and Sequencing Using Kit (ONT, SQK-LSK110), according to the manufacturer’s protocol (Nanopore Protocol, Ampcizons by Ligation, version ACDE_9110_v110- revC_10Nov2020). The ONT library was loaded onto a PromethION sequencer by using PromethION Flow Cell (ONT, FLO-PRO0002) and sequenced for 72h.

RNA extraction and cDNA synthesis for Illumina short-read sequencing. RNA was extracted from the single-nucleus suspension containing 300,000 nuclei by using the RNasy Mini Kit (74104), which involved on-column DNA digestion before RNA elution. cDNA was synthesized and amplified with NEBNext Single Cell/ Low Input DNA Synthesis & Amplification Module (E6421S) by following the manufacturer’s protocol.

Short-read library preparation and sequencing with Illumina. With 100 ng of cDNA input per sample, Illumina library prep was conducted with the Illumina DNA Prep (M) Tagmentation Kit (20187047) and IDT for Illumina Nextera DNA Library Prep (V5), index Set B20210, according to the manufacturer’s manual. Libraries were loaded on an Illumina NextSeq 500 with 2 × 150 bp Mid Output Kit by using the following read length: ten cycles Read1, ten cycles i7 index and 76 cycles Read2.

Evaluation of exon coordination in PTK2 by qRT-PCR. Neurons (Thy1+) and astrocytes (HepaCAM+) were isolated from fetal human brain tissue (n = 3, gestational weeks 19–20) using immunopanning. All fetal human brain tissue samples were obtained with informed consent under a Stanford University
Articles

No. of mapped read that overlap annotated exons

Performed circular consensus sequencing (CCS) with IsoSeq3 with the following alignment of PacBio long-read data. Using default SMRT-Link parameters, we types were assigned by identifying canonical marker genes for each cluster13,54–56. Approximation and projection (UMAP) non-linear reduction techniques. Cell both t-distributed stochastic neighbor embedding (tSNE) and uniform manifold the Louvain algorithm, setting the resolution parameter to 0.6. We performed expression percentages were regressed from each nucleus, and the matrix was log-normalized and scaled to 10,000 reads per cell. Next, we clustered cells using the PSI and corresponding peptide abundances (proteomics) using the subset of Trypsin peptides from an in silico digest of the exon sequences that were also identified and quantified in the proteomics dataset. Peptides that ambiguously map to multiple genes in an in silico digest of the UniProt mouse proteome were discarded. For both—the W values and the proteomics peptide abundances (mean over replicates)—we set a relative abundance threshold at 95% (of maximum abundance over cell types) to define their respective enriched cell type(s) and subsequently tested for overlap between both data sources.

Data processing and quality control for single-cell short-read analysis. The tenx Cell Ranger pipeline (version 3.1.0) was run on raw Illumina sequencing data to obtain single-cell expression matrices that were analyzed using Seurat version 3.1.1 (ref. 19). For both samples, nuclei that had unique gene counts of >7,500 or <200 or >4% mitochondrial gene expression were discarded. This yielded 7,314 nuclei for Cortex1 and 6,486 nuclei for Cortex2. UMI numbers and mitochondrial gene expression percentages were regressed from each nucleus, and the matrix was log-normalized and scaled to 10,000 reads per cell. Next, we clustered cells using the Louvain algorithm, setting the resolution parameter to 0.6. We performed both t-distributed stochastic neighbor embedding (tSNE) and uniform manifold approximation and projection (UMAP) non-linear reduction techniques. Cell types were assigned by identifying canonical marker genes for each cluster19,20. This cell type annotation was confirmed by aligning to the Allen Brain Atlas human cortical data.

Alignment of ONT long-read data. Long reads sequenced on the ONT PromethION were mapped using minimap2 (version 2.17-r943-dirty) using the previously described parameters17.

Calculation of on-target rate. For both long-read technologies, the on-target rate was calculated using the ‘intersect’ function from BEDTools (version 2.27.0) with this definition:

\[
\text{On} - \text{target rate} = \frac{\text{No. of mapped reads that overlap annotated exons}}{\text{Total no of mapped reads}}
\]

Calculation of normalized transcript coverage. Normalized transcript coverage was calculated using the ‘CollectRnaSeqMetrics’ function from Picard tools (version 2.25.7). A ‘refFlat’ gene annotation file was downloaded from http://hgdownload.cse.ucsc.edu/goldenPath/hg38/database/refFlat.txt.gz.

Subsampling of sequencing libraries. Reads were subsampled using the ‘sample’ command from seqtk (version 1.3-r106).

Calculation of a per-read exon ratio. The expected number of exons per Gencode gene was obtained by counting exons of each transcript and averaging for all annotated transcripts. Subsequently, the observed exons per read were divided by the expected number, yielding a ratio for each read.

In silico simulation of cDNA fragmentation. Sn50r-Seq long reads were truncated in silico so that a random number of 3’ nucleotides remained (normal distribution, mean = 250 and s.d. = 50) to simulate cDNA fragmentation. Then, 76 bp from the 5’ end of the remaining fragment were isolated to simulate the 76bp R2 of the 10x Illumina library. Normalized sequencing coverage was then calculated.

Barcode detection and identification of unique molecules from PacBio data. Cellular barcodes (16 nt) were detected using the ‘GetBarcodes’ function in scisorseqr33 (version 0.1.2). Given PCR duplication, one transcript per molecule—that is, barcoded-UMI–gene—was chosen for analysis.

Barcode detection for long-read transcripts obtained from ONT. Perfect matching barcodes were obtained similarly to the PacBio reads, however with some tolerance for sequencing errors, using the mapping information per read with white-listed UMIs as done previously17 with modifications:

- For each Illumina-sequenced UMI, all barcode–UMI 28mers were grouped by gene as a reference set.
- For every mapped ONT read, we compared only to the reference list for that gene.
- Sliding windows identified barcode–UMI candidates allowing ≤1 mismatch in the first 22 bp of each reference 28mer. We then allowed only ≤2 mismatches in the 28mer.

These steps were performed using a custom script.

Identification of unique molecules from ONT data. Given the ONT error rate, reads were more likely to undergo ‘molecule inflation’—that is, errors could result in one UMI being perceived as two different ones. To combat this, we proceeded as follows:

- Reads were grouped by barcode–UMI–gene and ordered by frequency.
- The Levenshtein distance (LevD) to the nearest barcode–UMI pair from the same gene was obtained.
- If LevD = 0, it was retained as an Illumina–confirmed molecule.
- If LevD = 1 or 2, the 28-bp sequence was corrected to match the Illumina reference, and, if the barcode–UMI–gene triplet was novel with respect to ONT data, it was retained.
- If LevD > 3 and the edit distance to any other already accepted UMI was > 5, the molecule was considered novel and retained.
- If LevD > 3 but the edit distance to any other already accepted UMI was 1 or 2, this UMI was corrected to the accepted UMI.

Following this sequencing error correction, only one read per barcode–UMI–gene triplet was retained. These steps were performed using a custom script.

Assigning TSS and polyA site to reads. We assigned the closest published TSS within 50 bp of the 3’ end of the read mapping16 as previously done. Likewise, we assigned the closest published polyA site within 50 bp of the 3’ end of the read mapping16.

PhastCons scores for exons, TSSs and polyA sites from 17 primates. PhastCons scores for 16 primate genomes aligned to the human genome were obtained from the UCSC website123. The scores were averaged over internal exons, TSSs and polyA sites using the bigWigAverageOverBed script from the UCSC Utilities package.

PhastCons scores for exons, TSSs and polyA sites from 17 primates.
Disease-associated exons for ASD, schizophrenia and ALS. ASD-associated exons (n = 3,482) were summarized from two studies and one review; 1,776 skipped exons from a comparison of ASD cases with controls (P < 0.05)8, 1,723 neurally associated alternatively spliced exons from ASD brains8 and 33 microexons associated with ASD and characterized functionally9. Schizophrenia-associated exons that were classified as alternative exon skipping events covering 1,107 exons were collected10. The list of 506 ALS-associated cassette exons was identified by comparing C9orf72 ALS brains with control brains11.

Alternative exon counting and categorization. Using all exons appearing as internal exon in a read, we calculated:

1. The number of long-read UMIs containing this exon with identity of both splice sites: \(X_{in}^{ts}\).
2. The number of long-read UMIs assigned to the same gene as the exon, which skipped the exon and ≥50 bases on both sides: \(X_{sk}\).
3. The number of long-read UMIs supporting the acceptor of the exon and ending on the exon: \(X_{p,a}\).
4. The number of long-read UMIs supporting the donor of the exon and ending on the exon: \(X_{p,d}\).
5. The number of long-read UMIs overlapping the exon: \(X_{ov}\).

Non-annotated exons with one or two annotated splice sites, ≥70 bases of non-exonic (in the annotation) bases, were excluded as intron retention events or alternative acceptors/donors.

We then calculated:

\[
\Psi_{\text{overall}} = \frac{x_{in} + x_{sk} + x_{p,a} + x_{p,d}}{x_{ov}}
\]

\[
\Psi_{\text{accept}} = \frac{x_{p,a}}{x_{ov}}
\]

\[
\Psi_{\text{donor}} = \frac{x_{p,d}}{x_{ov}}
\]

If

\[
0.05 \leq \psi_{\text{condition}} \leq 0.95 \quad \text{where} \quad \psi_{\text{condition}} = \psi_{\text{overall}}, \psi_{\text{accept}}, \psi_{\text{donor}}
\]

the exon was kept.

We then calculated the \(\Psi_{\text{score}}\) for each cell type from all long-read UMIs for that cell type if, and only if, \(X_{in} \geq 10\) for the exon and cell type in question. Otherwise, \(\Psi_{\text{score}}\) for the exon and cell type was set to ‘NA’.

Exon variability analysis. For each replicate, we defined a set of alternative exons that met each of the following criteria: (1) ≥10 supporting reads (inclusion + exclusion) in the pseudo-bulk; (2) 0.05 < \(\psi\) < 0.95 at the pseudo-bulk level; and (3) intron retention events were excluded. These steps yielded 5,855 (Cortex1) and 5,273 (Corne1) alternative exons. We defined a subset of alternative exons with ≥10 supporting reads in each of four major cell types (excitatory neurons, inhibitory neurons, astrocytes and oligodendrocytes). We divided alternative exons into three variability categories: (1) \(\psi_{\text{max}} - \psi_{\text{min}}\) ≤ 0.25; (2) 0.25 < \(\psi_{\text{max}} - \psi_{\text{min}}\) ≤ 0.75; and (3) \(\psi_{\text{max}} - \psi_{\text{min}}\) > 0.75. For each category, we plotted the exon length density using ggplot2. Then, for each disease, we compared disease-associated exons with all alternative exons for inclusion variability. Microexons were defined as exons with a length of ≤27 bp. Novel exons were defined as exons that are not described in the GENCODE version 34 annotation. To define a subset of novel exons that show high inclusion and/or high cell type variability, we plotted \((\psi_{\text{max}} - \psi_{\text{min}})\) against pseudo-bulk \(\psi\) and fit a loess curve to the data.

Gene variability analysis. Genes with disease-associated exons were isolated. log-normalized expression (transcripts per million (TPM)) values were obtained from the short-read 10x data. Variability per gene was defined as the minimum log-normalized expression (transcripts per million (TPM)) values were obtained as described above. For every gene used in the pseudo-bulk analysis, the exon pairs with the smallest \(\log_{10}(\text{odds ratio})\) were retained. The minimum PhastCons score for each pair was extracted and plotted against the absolute value of the log-odds ratio.

Cell-type-specific conservation for exon pairs. Exon coordination count data were split by cell type, including astrocytes, excitatory neurons, inhibitory neurons, oligodendrocytes or OPCs. Together with the log-odds ratio, we calculated an exon inclusion ratio, which is defined as the number of times both exons pairs are included in the sequencing data (in–in) divided by the sum of the in–in and out–out counts per exon pair. The minimum PhastCons value for each exon pair was selected and placed into two groups ([0,0.5] and [0.5,1]). We then plotted these two groups against the \(\log_{10}(\text{odds ratio})\) and the exon inclusion ratio as box plots.

Obtaining counts for exon–end site combinations. We obtained counts for exon–TSS and exon–polyA site combinations using a custom script. Specifically, per sample we counted the number of reads assigned to a given TSS and divided them into reads including a particular exon or skipping the exon. We proceeded similarly for exon–polyA site pairs. Only genes with ≥25 reads were used for further analysis.

Testing for exon–end site coordination. Testing for exon–end site coordination (here, with a \(\chi^2\) test) can be done either in pseudo-bulk or in each cell type. For each test, a \(n \times 2\) matrix per internal exon was generated, with the \(n\) TSS forming rows and inclusion and exclusion counts forming columns. An exon–TSS pair was tested only if the TSS was upstream of the intron preceding the exon, and the read extended to beyond the end of the following intron. For effect size, we used \(\Delta I\) (the maximum change in exon inclusion between reads associated to distinct TSS). Finally, we used a Benjamini–Yekutieli correction for multiple testing and reported the FDR value. We proceeded similarly for exon–polyA sites.

The \(\chi^2\) criterion and testability. To categorize exon pairs or exon–end site pairs as testable, we employed the following metrics. For each matrix \(M\) with elements \(m_{ij}\):

- The expected value for each element \(m_{ij}\) was defined as \(\sum_{i=1}^{m} \sum_{j=1}^{n} m_{ij}\).
- If the expected value in 80% (rounded to nearest integer) of elements is \(\geq 5\), and the expected value of all elements is \(\geq 1\), the \(\chi^2\) criterion is met, and the \(P\) value is calculated.
- If the median expected value is \(<5\) in any row or any column, then the RNA variable (that is, TSS, exon or polyA site) in that row or column is said to be constitutive.
- If none is met, we classify them as ‘low counts’.

Conservation analysis for exon–end site pairs. PhastCons scores for all TSSs were extracted as described above. For every gene in the pseudo-bulk analysis, the TSS–exon pair with the smallest \(\Delta I\) was chosen. For such exons, PhastCons scores of the associated TSSs were sorted by value. The TSS with the minimum PhastCons score was reported for that exon, and the Pearson’s product–moment correlation between the PhastCons score and \(\Delta I\) for that TSS–exon pair was calculated. Similar analysis was conducted for the exon–polyA site pairs.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
All data used for this study are publicly available in the Gene Expression Omnibus under accession number GSE178175. All data supporting the findings of this study are provided within the paper and its Supplementary Information. Source data for the main figures can be found at https://github.com/noush-joglekar/sn-code.

Code availability
The source code generated for this paper is publicly available at https://github.com/noush-joglekar/sn-code.

References
50. Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron* 89, 37–53 (2016).
51. Habib, N. et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat. Methods* 14, 955–958 (2017).
52. Grubman, A. et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. *Nat. Neurosci.* 22, 2087–2097 (2019).
53. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative \(C_{\text{T}}\) method. *Nat. Protoc.* 3, 1101–1108 (2008).
54.Lake, B. B. et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat. Biotechnol.* 36, 70–80 (2018).
55. Tasic, B. et al. Shared and distinct transcriptomic cell types across neocortical areas. *Nature 563*, 72–78 (2018).
56. Yao, Z. et al. A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation. Cell 184, 3222–3241 (2021).
57. Lebrigand, K., Magnone, V., Barby, P. & Waldmann, R. High throughput error corrected Nanopore single cell transcriptome sequencing. Nat. Commun. 11, 4025 (2020).
58. Lizio, M. et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 16, 22 (2015).
59. Herrmann, C. J. et al. PolyASite 2.0: a consolidated atlas of polyadenylation sites from 3′ end sequencing. Nucleic Acids Res. 48, D174–D179 (2019).
60. Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20, 110–121 (2010).

Acknowledgements
We thank J. McCormick and T. Baumgartner from Weill Cornell Medicine Flow Cytometry Core Facility for FACS assistance and D. Xu, X. Wang, A. Tan and J. Xiang from the Genomics Resources Core Facility for performing RNA sequencing. We thank C. Mason for use of the PromethION machine. We also thank Weill Cornell Medicine Scientific Computing Unit for use of their computational resources. H.U.T. is supported by NIGMS grant 1R01GM135247-01, Brain Initiative grant 1RF1MH121267-01, NIDA grant U01 DA053625-01 and the Feil Family Foundation. M.E.R. is supported by NIH grants 1R01NS105477, P01HD067244 and U54NS117170 and the Feil Family Foundation. L.G. is supported by NIH grants R01AG072758, U54NS100717 and R01AG054214 and the JPJ Foundation. T.A.M. is supported by NIH grants DA08259 and HL136520. L.C.N. is supported, in part, by the NIMH, NIDA, NINDS, NIDDK, NHLBI and NIAID under award number U1911164599 and by the NIDA under award number U01 DA53625 (to L.C.N., H.U.T. and T.A.M.). J.Q.T. is supported by NIH grant U19 AG062418. S.A.S. is supported by NIMH grant RO1MH125956 and the Brain and Behavior Foundation (grant 28172). E.D.J. and O.F. are supported by funds from the Howard Hughes Medical Institute. M.P. is supported by the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002, NAP2.0) through the Human Brain Tissue Bank at Semmelweis University. S.A.H. is supported by an Australian NHMRC Early Career Fellowship (APP1156531). Z.B. was supported by NKFIH K128247. D.T. was supported by FK128252. A.M. and A.D.P. are supported by the St. Petersburg State University (grant ID PURE 7303672). Computational analysis was performed with the help of the Research Park of St. Petersburg State University Computing Center.

Author contributions
S.A.H., W.H., A.J. and H.U.T. conceived the project and designed experiments. W.H., L.F., P.G.C. and M.P. performed experiments. S.A.H., A.J., C.F., N.B., A.P., A.M., J.J. and H.U.T. conducted computational analyses. T.A.M., L.C.N., O.F., D.T., M.E.R., E.J., Z.B., L.G. and H.U.T. supervised the project. V.M.Y.L. and J.Q.T. contributed key reagents. S.A.H., W.H., A.J. and H.U.T. wrote the manuscript. All authors participated in the review and editing of the manuscript.

Competing interests
L.C.N. has served as a scientific advisor for AbbVie, ViiV and Cytodyn for work unrelated to this project. L.G. is a founder of Aeton Therapeutics (which had no involvement in this study). A.B.L. is an employee of Agilent Technologies. The remaining authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41587-022-01231-3. Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41587-022-01231-3.

Correspondence and requests for materials should be addressed to Hagen U. Tilgner.

Peer review information Nature Biotechnology thanks Vladimir Benes and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Models for cell-type specific coordination. a. Model for TSS-exon combinations. b. Model for exon-polyA-site combinations. c. Model for distant exon combinations. d. Model for adjacent exon combinations. Colors indicate different cell types. TSS: transcription start site; polyA-site: polyadenylation site; OPCs: oligodendrocyte precursor cells.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a. Confirmed

- □ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- □ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- □ The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- □ A description of all covariates tested
- □ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- □ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- □ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  - Give P values as exact values whenever suitable.
- □ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- □ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- □ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

- Cells were sorted using the FlowJo (v10) software. RNA-seq reads were base-called using SMRT Link (PacBio reads) or Guppy (ONT reads). Reads were then mapped to the human genome using STARlong (v2.5.2b, PacBio reads) or minimap2 (v2.17-9433-dirty, ONT reads).

Data analysis

- Barcodes were identified using cellranger (v3.1.0, short-reads) or custom code (see below). Seurat (v3.1.5) was used for single-cell processing and visualization, cell clustering was done with the Louvain algorithm within Seurat. Pre-processing for long-read analysis was done using the scisorseq package (v0.1.2). The source code generated for this paper is publicly available at https://github.com/noush-joglekar/sn-code.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data used for this study is publicly available on GEO under the accession token GSE1178175. All data supporting the findings of this study are provided within the paper and its supplementary information. Source data for the main figures can be found at https://github.com/noush-joglekar/sn-code
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size          | No sample size calculation was performed. We only used a sample size of 2 as human brain samples are difficult to source. |
|----------------------|---------------------------------------------------------------------------------------------------------------|
| Data exclusions      | Nuclei were excluded from downstream analysis if they had exceptionally low (<200) or high (>7500) RNA counts or had high (>4%) fraction of reads mapping to mitochondrial genes. |
| Replication          | Replication was performed n=2 times. All key findings observed in Cortex1 were replicated in Cortex2.        |
| Randomization        | Not relevant to our study as we only used two human brain samples and no treatment was applied to them.       |
| Blinding             | Not relevant to our study as we only used two human brain samples and no treatment was applied to them.       |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ☒   | Antibodies           |
| ☒   | Eukaryotic cell lines |
| ☒   | Palaeontology and archaeology |
| ☒   | Animals and other organisms |
| ☒   | Human research participants |
| ☒   | Clinical data        |
| ☒   | Dual use research of concern |

Methods

| n/a | Involved in the study |
|-----|-----------------------|
| ☒   | ChIP-seq              |
| ☒   | Flow cytometry        |
| ☒   | MRI-based neuroimaging |

Human research participants

Policy information about studies involving human research participants

Population characteristics

All human tissues we use were supplied to us as de-identified post-mortem samples and are thus considered “non-human subjects research”. This is in compliance with NIH, Weill Cornell and Emory University policies, protocols, and guidance in working with human tissues.

Recruitment

-  

Ethics oversight

Regional and Institutional Committee of Science and Research Ethics of Scientific Council of Health, Code of Ethics of the World Medical Association, Semmelweis University Regional Committee of Science and Research Ethics, Stanford University

Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Approximately 30 mg of frozen tissue of each sample was dissected in a sterile dish on dry ice and transferred to a 2 mL glass tube containing 1.5 mL nuclei péré lysis buffer (MiliporeSigma, catalog no. L9286) on ice. Tissue was completely minced and homogenized to nuclei suspension by sample grinding with Dounce homogenizers. The nuclei suspension was filtered by loading through a 35 μm diameter filter and followed by centrifuging 5 min at 600 g and 4°C. The nuclei pellet was collected and washed with cold wash buffer, which consisted of the following reagents: 1X PBS, 20 mM DTT, 1% BSA, 0.2U/μl RNase inhibitor for three times. After removing the supernatant from the last wash, the nuclei were resuspended in 1 mL of 0.5 μg/ml DAPI and the concentration was estimated by using Countess II cell counter.

Instrument

Sony MA900 (Sony Biotechnology), Countess II cell counter (Thermo Fisher Scientific, catalog no. A27977).

Software

FlowJo V10.

Cell population abundance

Among the post-sort populations include over 100K nuclei, around 80%-90% are identified as the aiming nuclei population, which are determined by the DAPI-positive rate readout from Countess II cell counter (Thermo Fisher Scientific, catalog no. A27977).

Gating strategy

Most events were included in the FSC/SSC gate. Singlets were identified from FSC-W/FSC-H gate. Lastly, a distinct DAPI+ population was sorted.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.